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Transcatheter Aortic Valve Implantation for
Failing Surgical Aortic Bioprosthetic Valve
From Concept to Clinical Application and Evaluation (Part 1)
Nicolo Piazza, MD,* Sabine Bleiziffer, MD,* Gernot Brockmann, MD,* Ruge Hendrick, MD,*
Marcus-André Deutsch, MD,* Anke Opitz, MD,* Domenico Mazzitelli, MD,*
Peter Tassani-Prell, MD, PHD,† Christian Schreiber, MD,* Rüdiger Lange, MD, PHD*
unich, Germany
With an aging population, improvement in life expectancy, and signiﬁcant increase in the use of bio-
prosthetic valves, structural valve deterioration will become more and more prevalent. The operative
mortality for an elective redo aortic valve surgery is reported to range from 2% to 7%, but this percentage
can increase to more than 30% in high-risk and nonelective patients. Because transcatheter aortic valve
(TAV)-in-surgical aortic valve (SAV) implantation represents a minimally invasive alternative to conventional
redo surgery, it may prove to be safer and just as effective as redo surgery. Of course, prospective compari-
sons with a large number of patients and long-term follow-up are required to conﬁrm these potential ad-
vantages. It is axiomatic that knowledge of the basic construction and dimensions, radiographic identiﬁca-
tion, and potential failure modes of SAV bioprostheses is fundamental in understanding key principles
involved in TAV-in-SAV implantation. The goals of this paper are: 1) to review the classiﬁcation, physical
characteristics, and potential failure modes of surgical bioprosthetic aortic valves; and 2) to discuss patient
selection and procedural techniques relevant to TAV-in-SAV implantation. (J Am Coll Cardiol Intv 2011;4:
721–32) © 2011 by the American College of Cardiology Foundationo
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aDuring the last decade, the relative use of biopros-
thetic aortic valves has increased by nearly 80% (1).
Improvements in surgical techniques and valve
durability are likely to have fueled this increase (2).
Based on clinical and microsimulation studies,
several investigators suggest that we should lower
the age cutoff for bioprosthetic aortic valve replace-
ment from 65 to 60 years (3–5).
The actuarial freedom from reoperation for a
failing bioprosthetic valve is approximately 95%, 90%,
and 70% at 5, 10, and 15 years, respectively (6–10).
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Center, Munich, Germany; and the †Department of Anesthesiology,
German Heart Center, Munich, Germany. Dr. Piazza has reported that
he is a consultant for Medtronic. Dr. Mazzitelli has reported that he is
a proctor for Edwards Lifesciences. All other authors have reported that
they have no relationships to disclose.m
Manuscript received October 26, 2010; revised manuscript received
March 24, 2011, accepted March 31, 2011.In fact, the lifetime risk of reoperation decreases with
increasing patient age at the time of implantation
(Fig. 1) (11). More specifically, the lifetime incidence
f reoperation can be as high as 25% and 45% in
hose patients with a primary operation at 50 and 60
ears of age, respectively.
Over the last 2 decades, the mortality risk of
edo aortic valve surgery has decreased appreciably.
he operative mortality for an elective redo aortic
alve surgery is reported to range from 2% to 7%,
ut this percentage can increase to more than 30%
n high-risk and nonelective patients (12–22). Al-
hough redo surgery can be associated with low
ortality in selected patients, it can lead to signif-
cant morbidity including blood transfusion re-
uirements, wound infection, post-operative pain,
nd/or delayed recovery.
Transcatheter aortic valve implantation (TAVI)
ay represent an alternative treatment to conven-
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722tional aortic valve replacement for high or prohibitive surgical
risk patients (23–27). By virtue of its minimally invasive
nature, TAVI avoids sternotomy and cardiopulmonary by-
pass and can potentially reduce resource utilization by
accelerating patient recovery and reducing length of hospital
stay.
In 2007, Wenaweser et al. (28) reported the first case of a
transcatheter valve (Medtronic CoreValve system, Medtronic
CV Luxembourg S.a.r.l., Luxembourg, Germany) implanted
into a degenerated surgical aortic bioprosthesis. Since then,
numerous case reports of transcatheter aortic valve-in-
surgical aortic valve (TAV-in-SAV) implantation have been
described (29–46).
It is axiomatic that knowledge of the basic construction
and dimensions, radiographic identification, and potential
failure modes of SAV bioprostheses is fundamental in
understanding key principles involved in TAV-in-SAV
implantation. The goals of this paper are: 1) to review the
classification, physical characteristics, and potential failure
modes of surgical bioprosthetic aortic valves; and 2) to
discuss patient selection and procedural techniques relevant to
TAV-in-SAV implantation.
Bioprosthetic SAV
Types and construction. SAV
replacement with a bioprosthesis
can be performed using either a
stented or stentless valve (Table 1,
Fig. 2). Valve leaflets can be of
xenograft (specifically, porcine
aortic valve or bovine pericar-
ium) or homograft origin.
STENTED VALVES. Stented valves are typically constructed
sing a base ring that is covered by a fabric sewing cuff and
rom which a stent or frame arises at a right angle to support
he valve leaflets (Fig. 3). Depending on the model, the base
ing is either circular- or scalloped-shaped and may consist
f molded silicone rubber (with or without tungsten pow-
er), cobalt-chromium-tungsten (Haynes alloy), stellite, or
tainless steel. Modern day biological surgical valves are
ngineered using a flexible stent/frame that attempts to
bsorb, and thereby mitigate, the loading stress on the tissue
eaflets during valve closure. The stent/frame can be made of
obalt-nickel alloy (Elgiloy), polypropylene, acetyl homopo-
ymer (Delrin), acetyl copolymer (Celcon), or titanium and
ave metallic components. The base ring and stent/frame
an be exteriorized by Dacron, pericardium, polytetrafluo-
oethylene, or some other polyester fabric; at the level of the
ase ring, this exteriorization forms the basis of the suture
ing. It is evident by now that stented valves may or may not
e radiopaque. Correct positioning and deployment of trans-
atheter valves during a TAV-in-SAV procedure requires correct
Abbreviation
and Acronym
SAV  surgical aortic valve
TAVI  transcatheter aortic
valve implantation
TAV-in-SAV  transcatheter
aortic valve-in-surgical aortic
valveadiographic recognition of stented bioprostheses.Several dimensions characterize stented valves (Fig. 4).
o better appreciate these dimensions, it is important to
ecall the various components of the bioprosthesis: the
eaflets, the base ring and covering cloth (suture ring), and
he stent/frame. Thus, leaflet thickness and the suture ring
base ring and cloth) profile can influence the potential
pace for blood flow. The inner base ring diameter (com-
only referred to as the inner stent diameter) is measured
rom the inner surface to inner surface of the base ring.
he outer base ring diameter (commonly referred to as
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Figure 1. Lifetime Risk of Reoperation as a Function of Age at
Table 1. Classification of Stented and Stentless Bioprostheses on the
Basis of Tissue Type
Stented
Bovine Pericardial Porcine Aortic Valve
Edwards Perimount Medtronic Hancock I and II
Sorin Mitroﬂow Medtronic Modiﬁed Oriﬁce
Sorin Soprano Medtronic Mosaic
Carpentier-Edwards Supra-Annular Valve
St. Jude Medical Biocor/Epic
Stentless
Bovine Pericardial Porcine Aortic Valve Homograft
Sorin Freedom Medtronic Freestyle CryoValve
ATS Medical St. Jude Toronto SPV Ross procedure
St. Jude Biocor
Edwards Prima
CryoLife O’Brien
Biocor, Epic, and Toronto are products of St. Jude Medical (Minneapolis, Minnesota). CryoValve
and O’Brien are products of CryoLife (Kennesaw, Georgia). Freedom, Mitroflow, and Soprano are
products of SorinGroup (Saluggia, Italy). Perimount, Prima, andSupra-Annular Valve areproducts
of Edwards Lifesciences (Irvine, California). Freestyle, Hancock, Modified Orifice, and Mosaic are
products of Medtronic (Minneapolis, Minnesota).
SPV stentless porcine valve.Surgical Aortic Valve Replacement
ne val
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723the outer stent diameter) is measured from the outer
surface to outer surface of the base ring and thereby
excludes the thickness of the covering cloth. The outer
suture ring diameter (also known as the external diame-
ter) is measured from the outer undisturbed sewing cuff
surface to outer cuff surface.
Selection of prosthetic valve size is typically performed
intraoperatively using manufacturer-specific sizing tools and
can be influenced by factors such as operator experience,
philosophy or bias, and extent of leaflet resection and annular
decalcification. Whereas the inner base ring diameter is an
important factor influencing post-operative gradients, the
outer suture ring diameter typically determines the maximal
valve size that can be inserted. By reducing the thickness of the
base ring or profile of the sewing cuff, manufacturers can
maximize the inner base ring diameter for a given annulus size.
In addition to the diameter of the outer suture ring, the
position in which the prosthesis is inserted relative to the
annulus (i.e., intra- or supra-annular) can also influence max-
imal valve selection. Whereas the first-generation Hancock
(Medtronic Inc., Minneapolis, Minnesota) and Carpentier-
Edwards (Edwards Lifesciences, Irvine, California) valves were
Medtronic 
Freestyle
Medtronic 
Hancock II
Medtronic Mosa
Edwards Prima 
Plus
CE Perimount
Magna
CE Perimount
A
B
C
Figure 2. Types of Stented and Stentless Valves
(A) Stented pericardial bovine bioprosthetic valves. (B) Stented porcine aortic
These lists are nonexhaustive. CE  Carpentier-Edwards; SPV  stentless porcidesigned for intra-annular insertion, second- and third-generationvalves such as the Medtronic Mosaic, Carpentier-Edwards
Magna (Edwards Lifesciences), and Sorin Soprano (Sorin Group,
Milan, Italy) are designed to be implanted supra-annularly.
Supra-annular positioning allows the aortic sinuses to
accommodate the bulk of the cuff tissue and thereby
liberate the left ventricular outflow tract from obstructive
material. What follows then, is that a supra-annular
prosthesis allows for a larger inner stent diameter in a
given patient.
Of particular note, the manufacturer’s labeled valve size
(in millimeters) does not match the inner base ring diameter
or any significant hemodynamic-related dimension of the
valve (47–49). The labeled valve size of most manufacturers,
however, corresponds to the outer base ring diameter. In
reality, there is no homogeneity across manufacturers when it
comes to labeling valve size. This fact becomes important when
comparing the clinical and hemodynamic outcomes of “simi-
lar” labeled valve sizes from different valve manufacturers.
Despite the call for standardization of “valve size labeling” from
several surgical groups, discrepancies among manufacturers
remain (47–49). Later on, we will discuss the importance of
the inner base ring diameter as it relates to transcatheter valve
 Jude Toronto 
SPV
Sorin Freedom
Sorin Mitroflow
CE Porcine SAV
CE Perimount
Magna Ease
Biocor
bioprostheses. (C) Stentless bioprosthetic valves.
ve.ic
St.
valvesize selection for TAV-in-SAV.
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724Online Appendix 1 provides the dimensions of the outer suture
ring diameter, outer base ring diameter, inner base ring diameter,
and valve height for commonly inserted stented aortic valves.
STENTLESS VALVES. Stentless valves, as the name implies,
Elgiloy wireform
stent
Elgiloy
Polyester 
stent p
A
Elgiloy wireform
stent
Elgiloy
Polyester 
stent p
Elgiloy
Polyester 
stent p
Elgiloy wireform
stent
Acetyl homopolymer stent
Stellite ring 
Haynes Alloy eyelets 
Me
Ha
C
Silicone base
ring
Acetyl stent
B
Figure 3. Stented Bioprosthetic Valves Consist of a Base Ring and Stent W
(A) Carpentier-Edwards Perimount (Edwards Lifesciences, Irvine, California) bov
Minnesota) porcine aortic valve bioprostheses. (C) Sorin Mitroﬂow (Sorin Groudo not have a stent/frame or base ring. As described inTable 1, these valves may be of heterograft, autograft, or
homograft origin. A thin strip of nonexpansible cloth (e.g.,
Dacron) may cover the inflow tract to provide extra support
and facilitate the suturing of the prosthesis to the left
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725With the lower profile and nonobstructive properties of
stentless valves came the anticipated reduction in transval-
vular gradients and improved flow characteristics with
respect to stented valves (50,51). Furthermore, these valves
were expected to perform better in small aortic roots (52).
Notwithstanding the technical demands required for stent-
less procedures, there have been conflicting reports on their
purported benefits (53,54).
With a few exceptions, the labeled size of a stentless valve
corresponds to its outer diameter (in millimeters). With the
absence of a rigid base ring, the relevant dimensions of a
stentless valve include its inner and outer diameter. Online
Appendix 2 provides the dimensions of the inner and outer
diameters and height for commonly inserted stentless aortic
valves.
Radiographic/Fluoroscopic Identification
of SAV Bioprostheses
Stented valves are identified by recognizing radiopaque
components of the base ring and/or stent on fluoroscopy
(Fig. 5) (55,56). Stentless valves, on the other hand, do not
have any radiopaque components. With either valve type,
calcifications may help with identifying the margins and
location of the prosthesis.
Fluoroscopic analysis of the prosthesis should begin with
identification of the base ring (Figs. 3 and 5). The base ring
may or may not be radiopaque. Furthermore, the shape of
the base ring (circular, boat-, or hammock-shaped) and
whether the ring is open or closed will help distinguish
between valve types.
The second step requires characterization of the stent/
frame. Again, this component may or may not be ra-
diopaque. The base ring can be a continuous structure
B
A
D
BA
Figure 4. Dimensions of Stented Bioprosthetic Valves
(A) Diagrammatic representation of stented bioprosthetic valve dimensions wh
and D  outer sewing ring diameter. (B) Inferior (ventricular) view of stentedwith the stent; in these cases, analysis of the angle with rwhich the struts emerge from the base ring can be
informative (Figs. 5E to 5G). In some cases, such as with
the Medtronic Hancock II or Mosaic prosthesis, the stent
struts are radiolucent except for tiny circular eyelets near
their apices (Figs. 5B to 5D).
Causes and Mechanisms of
Bioprosthetic Valve Failure
Time-related structural valve dysfunction leading to regur-
gitation or stenosis is the major drawback of bioprosthetic
valves. Fortunately, the vast majority of valve failures are
nonfatal and progress slowly; if identified in a timely
manner, an elective redo surgery can be performed with relative
safety. Structural valve dysfunction is age-dependent. In fact, it
is nearly uniform by 5 years in those 35 years of age, but
occurs in only 10% in those 65 years of age within 10 years
Fig. 1).
It is beyond the scope of this manuscript to provide a
etailed description of the explant pathology and modes of
ioprosthetic valve failure (57–60). Failure modes can be
nfluenced by: 1) host metabolic pathways; 2) bioprosthesis
ngineering and chemistry (e.g., leaflet suturing material,
tent post flexibility, prosthesis fabric covering, leaflet fixa-
ion process); and 3) mechanical loading effects (e.g., leaflet
exural stress/strain). Broadly speaking, bioprosthetic valve
ailure can be the result of calcification, wear and tear,
annus formation, thrombosis, and/or endocarditis (Fig. 6).
Leaflet tissue deterioration, whether calcific or noncal-
ific, is the major cause of bioprosthetic valve failure
57–60). Although the glutaraldehyde fixation process of
ioprosthetic heart valves is intended to promote tissue
urability by creating stable cross links between collagen
bers and render the heterograft material biologically inert,
C
C
 outer stent diameter; B  inner stent diameter; C  prosthesis height;
sthesis. (C) Side view of stented bioprosthesis.ere Aesidual glutaraldehyde-derived polymers may serve as
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726Figure 5. Radiographic Appearances of Various Stented Bioprosthetic Valves
(A) The Hancock standard valve has a radiopaque Haynes alloy ﬂat base ring. (B) The Hancock Modiﬁed Oriﬁce valve has a radiopaque ﬂat base ring (Haynes
alloy) and metal eyelets (Haynes alloy) located at the apices of each stent post. (C) The Medtronic Hancock II valve has a radiopaque saddle-shaped base ring
(Haynes alloy) and metal eyelets (Haynes alloy) located at the apices of each stent post. (D) The Medtronic Mosaic valve has radiopaque metal eyelets only. (E)
The Carpentier-Edwards (CE) Porcine Standard valve has a radiopaque continuous wire form (Elgiloy) that outlines the stent posts (U-shaped loops) and the base
ring between the stent posts. The base ring is otherwise radiolucent. (F) The CE Porcine Supra-Annular Valve (SAV) is similar to the CE Porcine Standard valve (E)
except that the CE porcine SAV has “less sharp” transition angles between base ring and stent posts. (G) The CE Pericardial valve has a ﬂattened radiopaque
base ring with 3 holes. A narrow wire form (Elgiloy) outlines the 3 stent posts and the base ring in between. (H) The CE Perimount standard has a radiopaque
base ring that contains multiple holes and a separate narrow wire form (Elgiloy) that outlines the stent posts and the base ring in between. As shown in Figure 3,
the base ring of the CE Perimount can differ depending on the model (e.g., Magna, Magna Ease). Furthermore, the metal stent posts of the CE pericardial valves
form a very tight “U,” whereas the CE porcine valves have a more open “U.”
Continued on next page.
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727calcium-binding sites that promote calcium-phosphate pre-
cipitates. Furthermore, toxic glutaraldehyde may result in
cell death of bioprosthetic valve leaflets and host fibroblasts/
macrophages. The mitochondria of dead cells, rich in
phosphate, can be an additional source of calcium-binding
sites. For these reasons, anticalcification treatments (e.g.,
Figure 5. Continued
(I) The Sorin Mitroﬂow valve (left) and Sorin Soprano valve (right) have a
radiopaque saddle-shaped base ring. The stent posts are not visible. In
contrast to the Sorin Mitroﬂow, the Soprano valve has a narrower base ring
proﬁle. (J) The Ionescu-Shiley Standard valve has a radiopaque base ring
with multiple holes that is continuous with the stent posts that are charac-
terized by 3 holes. (K) The Ionescu-Shiley low proﬁle valve has 3 narrow
wire form arcs separated by radiolucent areas highlighting the base ring.
Figures 5A, 5E, and 5K are reprinted, with permission, from Mehlman et al.
(56). Figures 5D, 5F, 5G, and 5K are reprinted, with permission, from Mehl-
man (55). Figures 5B and 5C are reprinted, with permission, from Mehlman
DJ. A pictorial and radiographic guide for identiﬁcation of prosthetic heart
valve devices. Prog Cardiovasc Dis 1988;30:441–64.Edwards ThermaFix, Medtronic AOA) serve to reduce mpotential binding sites by: 1) residual glutaraldehyde sub-
straction; 2) phospholipid extraction; and/or 3) terminal
liquid sterilization.
Calcific deposits have a propensity to develop in areas
where leaflet flexion and stress are greatest; that is, at the
basal and commissural attachment points. Approximately
three-fourths of patients with leaflet calcification and tears
suffer from aortic regurgitation (57–60). Because significant
aortic regurgitation can be associated with large stroke volumes,
transcatheter prostheses can be difficult to position accurately
unless rapid pacing is performed during deployment.
Pannus represents a host tissue response and develops at
the host-prosthesis interface. Early pannus is composed of
myofibroblasts, fibroblasts, and capillary endothelial cells.
Overtime pannus may calcify. Some pannus formation over
the suture is normally expected and functions to form a
nonthrombogenic surface. When exuberant, however, it
may extend to the leaflets and contribute to leaflet stiffening
and dysfunction. Pannus formation is usually mild and can
be detected in the vast majority (70%) of explanted valves.
Thrombosis and endocarditis occur less frequently than the
aforementioned modes of bioprosthetic failure, occurring at a
rate of 0.2% per year and 1.2% per year, respectively (61).
In elective, low-risk patients, redo surgery can be per-
formed with a low mortality risk, which is comparable to the
primary valve operation (13–15,19,20). Still, there are pa-
tients for whom a second operation carries an unacceptable
risk for the physician and/or patient. Furthermore, redo
surgery can be associated with significant morbidity such as
blood transfusions, renal failure, wound infection, post-
operative pain, and delayed recovery. For these patients,
TAV-in-SAV can provide a lesser invasive approach poten-
tially associated with lower morbidity and mortality than
conventional surgery.
Procedural Aspects of TAV-in-SAV Implantation
Transcatheter valve size selection. Technical details of the
rimary valve surgery will help confirm the type and size of
ioprosthesis. Transcatheter valve size selection depends on
number of factors such as the manufacturer’s internal stent
iameter, information gleaned from multiple imaging mo-
alities (specifically transesophageal echocardiography,
ransthoracic echocardiography, and multislice computed
omography), mode of failure, and hemodynamic expecta-
ions based on patient body size and risk profile.
As was previously stated, a discrepancy exists between the
abeled valve size and the internal stent diameter of the
rosthesis (47– 49). A reference table, such as provided in
nline Appendix 1, should be used to obtain the internal
tent diameter of the prosthesis and guide transcatheter valve
ize selection. Severe calcification or excessive pannus growth,
owever, may cause a mismatch between the measured and
anufacturer listed internal stent diameter.
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728When TAVs are implanted into native aortic valves, pros-
theses are typically oversized relative to the annulus diameter by
10% to 30%. Whether sizing principles should differ for a
TAV-in-SAV implantation, and even more specifically, be-
tween nondistensible stented valves and “somewhat” distensi-
ble stentless valves is yet to be determined. In the absence of
any firm evidence or recommendations, we continue to use the
manufacturer’s sizing principles (23- and 26-mm Edwards
Sapien valve for aortic annuli measuring 18 to 21 mm and 22
to 25 mm, respectively; 26- and 29-mm Medtronic CoreValve
for aortic annuli measuring 20 to 23 mm and 24 to 27 mm,
respectively). Inevitably, because of the restricted dimensions of
the internal base ring, the majority of TAV-in-SAV procedures
will be performed with the “smaller” sized transcatheter valve.
An undersized transcatheter valve may increase the risk of
paravalvular leak or migration/embolization. On the other
hand, oversizing may lead to geometrical distortion of the
transcatheter valve leaflets and influence its durability.
Experimental work in this field is extremely limited.
Using pulse duplicators, Azadani et al. (62) recently exam-
ined the hemodynamic behavior of a 23-mm TAV im-
planted within degenerated small-sized Carpentier-Edwards
Perimount bioprostheses (19, 12, and 23 mm). The inves-
tigators noted that the rigid base ring and the stent posts of
CWear and tear
Endocarditis
A B
D
Figure 6. Pathological Specimens Showing the Most Common Reasons for
(A) Wear and tear. (B) Calciﬁc degeneration. (C) Pannus. (D) Endocarditis. (E) T
for bioprosthetic valve failure.the bioprosthesis prevented full expansion of the transcath-eter valve in all cases. Although the transvalvular gradients
decreased significantly in the 23- and 21-mm bioprostheses,
there was no improvement within the 19-mm Perimount
bioprosthesis. Furthermore, there was significant central aortic
regurgitation with the 19-mm Perimount bioprosthesis. The
investigators concluded that the rigid base ring and stent posts
appear to offer adequate anchorage for the TAV. With the
currently available transcatheter aortic valves, a TAV-in-SAV
implantation within a 19-mm surgical bioprosthesis may yield
unacceptable hemodynamics and should be discouraged.
Pre-implant balloon aortic valvuloplasty. As will be appre-
ciated in the summary of published case reports, practice
patterns across hospitals are heterogeneous. The benefits
and/or risks associated with pre-implant balloon dilation are
currently unknown. During routine TAVI, pre-implant
balloon aortic valvuloplasty, through cracking of calcific
deposits, is believed to improve the annular “seating space”
and allow for maximal transcatheter valve expansion. This
concept may apply for TAV-in-SAV when severe calcifica-
tion is the mode of failure. In other situations, the value of
dilating a “nondistensible” stented valve can be debated.
Furthermore, there is concern that pre-implant balloon
aortic valvuloplasty within degenerated bioprostheses may
cause friable material to embolize. According to the American
ication Pannus
Thrombus
C
osthetic Valve Failure
bus. Wear and tear (A) and calciﬁcation (B) are the most common reasonsalcif
E
Biopr
hromCollege of Cardiology/American Heart Association and Eu-
Final
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729ropean Society of Cardiology valvular heart disease guidelines,
percutaneous balloon interventions should be contraindicated
in the therapy of stenotic left-sided bioprostheses (63,64). In
cases of homograft degeneration, the “aortic wall” of the
prosthesis is frequently calcified; anecdotally this may increase
the risk for root rupture during balloon aortic valvuloplasty.
Positioning and deployment. There are a number of con-
siderations during the positioning and deployment phases of
a TAV-in-SAV procedure. Radiopaque components of
stented valves (base ring and/or stent) serve as perfect markers
for positioning of transcatheter valves (Figs. 7 and 8). Other
possible markers for positioning include the use of repeat
aortic angiograms, transesophageal echocardiography, a pig-
tail catheter lying in the base of the prosthetic leaflets,
and/or identification of calcific spots.
The fluoroscopic viewing angle for valve positioning
and deployment should be perpendicular to the base ring
Figure 7. Munich Case Example: Transapical 23-mm Edwards Sapien Impla
(A) Fluoroscopic identiﬁcation of the Medtronic Mosaic bioprosthesis. (B) Position
Mosaic valve located near the apices of the stent posts. The 23-mm Edwards Sapi
has a height of approximately 15 mm. In this case, the upper edge of the Edward
Medtronic Mosaic valve. (C) Balloon deployment of the Edwards Sapien valve. (D)of the surgical prosthesis (if visible). Otherwise, contrastaortography can help select the correct viewing angle.
Furthermore, the transcatheter valve should lay coaxial
within and lay 3 to 4 mm below the base ring of the
surgical prosthesis. Because of its “direct access” route,
transapical valve implantation may facilitate coaxial
alignment of the transcatheter valve. As opposed to the
retrograde approach, the transapical approach may facil-
itate crossing of the stenotic bioprosthetic valve.
A significant number of patients with degenerated
aortic valve bioprostheses have existing aortic regurgita-
tion. In these cases, rapid pacing can be used to reduce
cardiac output and stabilize positioning of the transcath-
eter valve.
During SAV replacement, the stent posts of surgical
prostheses are oriented in line with the native commissures
and away from the coronary ostia. It is possible, however,
that the surgical bioprosthesis is oriented wrongly and the
in 21-mm Medtronic Mosaic Bioprosthesis
the Edwards Sapien valve relative to the radiopaque eyelets of the Medtronic
ve has a height of approximately 14 mm. The 21-mm Medtronic Mosaic valve
en valve should be either aligned or 1 to 2 mm below the eyelets of the
contrast aortography revealed no aortic regurgitation.nted
ing of
en val
s Sapistent posts come to overlie the coronary artery ostia. This
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730situation may lead to coronary artery compromise during the
TAV-in-SAV deployment (for a case example please refer
to the accompanying article in this issue of JACC: Cardio-
vascular Interventions by Piazza et al. (65) describing the
German Heart Center Munich experience with TAV-in-
SAV).
Durability issues. As long as there are no long-term
xperimental or clinical data, we can only speculate on
he potential durability issues associated with TAV-in-
AV implantation. Underexpanded transcatheter valves
ay be associated with leaflet redundancy and increased
eaflet stresses that negatively influence durability. As
pposed to the native stenotic aortic valve that is typically
ssociated with asymmetric calcifications and an oval
nnulus, the rigid base ring of a stented valve may provide
he necessary platform to produce a nearly circular
ranscatheter valve that allows for optimal leaflet geom-
try and durability.
ther Indications: Transcatheter Valve
mplantation for Failing Surgical Prostheses
There is also interest in transcatheter valves for failing
surgical mitral valve bioprosthesis (66), surgical mitral valve
repair (i.e., valve-in-a-ring) (67), and surgical pulmonary
valve bioprosthesis (44). Transcatheter valve replacement
with the Medtronic Melody or Edwards Sapien prosthesis
for a failing right ventricle–pulmonary artery homograft is
well established. Specific considerations for these applica-
tions are beyond the scope of this article.
Conclusions
With an aging population, improvement in life expectancy,
and significant increase in the use of surgical bioprostheses,
structural valve deterioration will become more and more
prevalent. TAV-in-SAV implantation, because of its mini-
Figure 8. TAV-in-SAV Implantation Using the Medtronic CoreValve Prosthes
Medtronic CoreValve prosthesis successfully implanted within (A) Edwards Perimount,mally invasive character, may prove to be a safer and just aseffective option than redo surgery. Of course, prospective
comparisons with large number of patients and long-term
follow-up are required to confirm these potential advantages.
TAV-in-SAV implantation may even “disrupt” conven-
tional surgical practice patterns. Eventually, we may observe
a larger number of younger patients (age 60 years) being
referred for surgical bioprosthetic valve replacement given
the option of a TAV-in-SAV implantation in case of future
structural valve dysfunction.
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APPENDIX
For the dimensions of some commonly inserted stented and stentless devices,
please see the online version of this article.
